Nicotinamide mononucleotide

Also called NMN

Nicotinamide mononucleotide has been studied in 793 papers since 1987: 33 trials and 16 observational studies in people, 414 in animals, 164 in cells, 147 reviews; 178 in the past year. Its furthest trials in people are at phase 2. The newest story, Nov 6, 2026: “Lactate-linked protein change limits death in cultured ovarian cells”.

InterventionNAD+ precursorsPhase 2

793 papers study it88 more mention it1,453 findingsUpdated

PubChemChEBIMeSH

Research on it is growing 16% faster than aging research as a whole: 40 papers in the latest year counted

Part of David Sinclair's daily regimen in LifespanMore supplements

28 new papers in 30 daysSee all 826 papers on nicotinamide mononucleotide

At a glance

Nicotinamide mononucleotide extends lifespan in G608G HGPS mice; independent labs reproduce higher mouse NAD+ and lower inflammation, although inflammation results disagree. Human trials report increased blood NAD+, while a trial shows no clear brain NAD+ effect. Some human papers declare developer ties; seven trials concern aging, and two trials ended over a year ago without posted results or citing papers.

1,453 findings in 531 papers from 2011 to 2026, 62 of them since April 2026

Independent labs found the same change in cells, mice and people. 207 independent labs in 33 countries; 11 trials, 8 about aging, 2 with no results posted.

“Compared with the placebo, NMN supplementation was associated with a statistically significant but modest reduction in resting DBP (WMD, -2.15 mmHg; 95% CI: -3.68 to -0.61).”
Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsNutrients2026doi:10.3390/nu18060890

35 of its findings point the other way.

Cells, mice and humans: replicated by independent labs. Worms or flies: a single group.
  • 207 independent labs in 33 countries
  • 35 findings against
  • 11 trials, 8 about aging, 2 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 216 of 1,378 findings with company ties
  • 6 of 11 trials sponsored by its developers
  • Human trial32
  • Humans15
  • Animals394
  • Model organisms8
  • Cells134
  • In silico8

29 studies gave nicotinamide mononucleotide to people and measured what changed.

What changedDesignPeopleSource

up: Increases retinal thickness+1.14 ± 2.85 μm (NMN) vs -2.77 ± 3.30 μm (placebo); p = 0.006

no change: Has no effect on best-corrected visual acuity

no change: Has no effect on adverse events

Randomized trial24 weeks7 peopleMen65 years or olderOlder adults; temporal subretinal field of the outer ETDRS circle, relative to placeboGeriatrics & gerontology international, May 1, 2026

down: Decreases diastolic blood pressureWMD -2.15 mmHg

no change: Has no effect on systolic blood pressure

down: Decreases systolic blood pressureWMD -3.94 mmHg

Review of trials349 people pooled60 years and olderOlder adults; Patient cohortsNutrients, Mar 11, 2026

down: Decreases mitochondrial content

Randomized trial7 d11 peoplemale22.8 ± 1.5 yYoung, non-athletic males with prior weight-training experienceJournal of the International Society of Sports Nutrition, Feb 18, 2026

no change: Has no effect on body listeningp = 0.102

Randomized trial60 peoplemale studentsmean age 19.0 ± 0.7 yearsMale students majoring in physical educationScientific reports, Feb 6, 2026

up: Increases NAD+

no change: Has no effect on NAD+

Trial4 weeks12 people6 females and 6 males30 to 85 yearsHealthy individuals and persons with Parkinson's diseaseiScience, Jan 27, 2026

What did lifespan studies of nicotinamide mononucleotide find?

DrugAge

DrugAge records 1 result from 1 paper: 1 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.

What did studies of nicotinamide mononucleotide find?

527

Studies of nicotinamide mononucleotide measured 527 outcomes; the most studied are NAD+ (42 studies), apoptosis (23) and oxidative stress and ROS signaling (20).

NAD+

upin mice23upin reviews5upin humans4upin cells3+7

42 studies
  1. Nicotinamide mononucleotide showed no clear effect on NAD+ in humans.

    “Like NR, NMN supplementation did not lead to a significant detectable change in brain NAD levels over time, nor at the end of supplementation on day 8 (LME, p = 5.57x10−2), or on day 9 (LME, p = 0.24), when blood NAD levels were at their peak ( G).”

    Human trialbrain4 weeksn = 6

    The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation

    iScience

  2. Nicotinamide mononucleotide increases NAD+ in humans.

    “Supplementation with NMN resulted in similar changes of blood NAD levels over time.”

    Human trialblood4 weeksn = 6

    The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation

    iScience

  3. Nicotinamide mononucleotide increases NAD+ in humans.

    “MIB‐626 treatment resulted in a significant increase in blood NAD+ levels from baseline to Day 14 compared to placebo.”

    Human trial14 consecutive daysn = 42

    Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial

    FASEB bioAdvances

  4. Nicotinamide mononucleotide increases NAD+ in humans (versus placebo).

    “significantly higher blood levels of NAD + and its metabolites”

    Human trialversus placebo250 mg/day12 weeks

    Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study

    GeroScience

  5. Nicotinamide mononucleotide increases NAD+ in humans (dose-dependent).

    “A significant dose-dependent increase in NAD concentration change (NADΔ) was observed following NMN supplementation”

    Human trialdose-dependentblood300, 600 or 900 mg daily60 daysn = 80

    Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration

    Mechanisms of ageing and development

  6. Nicotinamide mononucleotide increases NAD+ in C. hircus cells (poor-quality oocytes).

    “Supplementation with nicotinamide mononucleotide (NMN) restored NAD levels”

    Cellspoor-quality oocytesoocyte

    Cell stress linked to disrupted metabolism in goat egg cells

    bioRxivPreprint

  7. Nicotinamide mononucleotide increases NAD+ in mice (diet-induced metabolic syndrome) (1.50 ± 0.28 to 1.96 ± 0.31 and 2.34 ± 0.35 pmol/mg).

    “lens NAD+ increased from 1.50 ± 0.28 to 1.96 ± 0.31 pmol/mg and 2.34 ± 0.35 pmol/mg, respectively.”

    Animalsdiet-induced metabolic syndromelens150 and 300 mg/kg/daymale and females

    Nicotinamide mononucleotide reduced lens stiffness in mice

    Frontiers in microbiology

  8. Nicotinamide mononucleotide increases NAD+.

    “Administering exogenous NAD+ precursors, such as Nicotinamide Mononucleotide (NMN) or Nicotinamide Riboside (NR), successfully restores the NAD+ pool”

    Review

    The Biochemical Landscapes Of Longevity: Interplay Between Mitochhondrial Dysfunction, Nutrient Sensing Pathways, And Metabolic Strategies To Halt Aging

    International Journal of Medical Science and Public Health Research

  9. Nicotinamide mononucleotide increases NAD+ in cells.

    “NMN elevates intracellular NAD+ levels”

    Cells

    AIE-pharmacology: Acacetin and NMN co-delivery rescues sperm motility

    Materials today. Bio

  10. Nicotinamide mononucleotide increases NAD+ in aged mice.

    “This treatment significantly increased ovarian NAD+ and ATP”

    Animalsin aged miceovary500 mg/kg/day10 daysfemales

    NMN Can Restore Ovarian Reserve in Aged Mice by Upregulating NAD⁺/SIRT1/PGC-1α Signaling Pathway and TOMM20 Expression, and Improve in Vitro Development of Aging Oocytes

    Reproductive sciences (Thousand Oaks, Calif.)

All 43

More on NAD+

Apoptosis

downin mice8downin human cells5downin mouse cells4downin pigs2+4

23 studies
  1. Nicotinamide mononucleotide inhibits apoptosis in human cells (testosterone-treated cells).

    “NMN promoted SIRT2-mediated deacetylation of LDHA at K119, which enhanced glycolytic activity, promoted proliferation, and inhibited apoptosis in ovarian GCs.”

    Cellstestosterone-treated cellsKGN cell

    Nicotinamide mononucleotide supplementation improves polycystic ovary syndrome by activating silent regulatory protein 2 mediated lactate dehydrogenase A lysine 119 deacetylation to enhance glycolytic activity

    International journal of biological macromolecules

  2. Nicotinamide mononucleotide decreases apoptosis in human cells (H2O2-induced and AA-derived hair follicle stem cells).

    “cell apoptosis and oxidative stress were repressed”

    CellsH2O2-induced and AA-derived hair follicle stem cells2 mM

    NMN alleviates oxidative stress damage in alopecia areata by activating SIRT7 and promoting glutamine metabolism

    Biochimica et biophysica acta. Gene regulatory mechanisms

  3. Nicotinamide mononucleotide decreases apoptosis in aged mice.

    “reduced oocyte oxidative stress (ROS) and apoptosis”

    Animalsin aged miceoocyte500 mg/kg/day10 daysfemales

    NMN Can Restore Ovarian Reserve in Aged Mice by Upregulating NAD⁺/SIRT1/PGC-1α Signaling Pathway and TOMM20 Expression, and Improve in Vitro Development of Aging Oocytes

    Reproductive sciences (Thousand Oaks, Calif.)

  4. Nicotinamide mononucleotide inhibits apoptosis in human cells (compared with CG).

    “In addition, NAD+ effectively reduced apoptotic activity in decidualizing hEnSCs compared with the CG.”

    Cellscompared with CGendometrial stromal cells

    Sequencing Analysis Reveals Potential NAD+-Regulated Mechanisms in Endometrial Stromal Cell Decidualization Prior to Embryo Implantation

    Clinical and Experimental Obstetrics & Gynecology

  5. Nicotinamide mononucleotide decreases apoptosis in human cells (H2O2-induced oxidative stress in ARPE-19 cells).

    “both free NMN and NMN-GNPs significantly attenuated H2O2-induced apoptosis and cellular senescence in ARPE-19 cells”

    CellsH2O2-induced oxidative stress in ARPE-19 cellsfreeretinal pigment epithelium

    Enhancing retinal cells anti-attenuation under oxidative stress by NMN-loaded gelatin nanoparticles via efficiently intracellular delivery

    International journal of biological macromolecules

  6. Nicotinamide mononucleotide decreases apoptosis in glycerol model of heme protein-mediated AKI, compared with vehicle.

    “reduced apoptosis as assessed by terminal deoxynucleotidyl transferase-mediated digoxigenin-deoxyuridine nick-end labeling staining”

    Animalsin glycerol model of heme protein-mediated AKI, compared with vehiclekidneyday 1 after HP-AKI induction

    NAD + -Boosting Ameliorates Heme Protein-Mediated Acute Kidney Injury

    Kidney360

  7. Nicotinamide mononucleotide decreases apoptosis in mice after ischemia/reperfusion, measured by cleaved caspase 3, BAX and BCL-2.

    “NMN ameliorated the apoptosis after ischemia/reperfusion through down-regulation of cleaved Caspase 3, BAX and up-regulation of BCL-2.”

    Animalsafter ischemia/reperfusion, measured by cleaved caspase 3, BAX and BCL-2

    β-Nicotinamide mononucleotide activates the SIRT1/NF-κB pathway to alleviate ischemia reperfusion injury after lung transplantation

    Journal of translational medicine

  8. Nicotinamide mononucleotide inhibits apoptosis in human cells (H2O2-induced cell death).

    “NMN could effectively inhibit the apoptosis and ferroptosis pathways, thus protected cells from H2O2-induced cell death”

    CellsH2O2-induced cell deathA549 cells

    Protective effects of nicotinamide mononucleotide on DNA damage and cell death in A549 cells and aging in C. elegans caused by hydrogen peroxide

    Mutation research. Genetic toxicology and environmental mutagenesis

  9. Nicotinamide mononucleotide decreases apoptosis in mice during cyclophosphamide treatment.

    “reduced reactive oxygen species (ROS) levels, alleviated DNA damage, and reduced apoptosis”

    Animalsduring cyclophosphamide treatmentovary14 daysfemales

    Nicotinamide mononucleotide protects ovarian function and oocyte developmental competence during chemotherapy

    Journal of ovarian research

  10. Nicotinamide mononucleotide decreases apoptosis in pigs (maternal supplementation in sows).

    “declined oxidative stress and apoptosis”

    Animalsmaternal supplementation in sowsplacenta0.2 g per dayfemalesn = 24

    Maternal β-Nicotinamide Mononucleotide Supplementation Reduces the IUGR Rate by Improving Mitochondrial Function in the Placenta of Sows via AMPK/PGC-1α Pathway

    Molecular nutrition & food research

All 23

More on Apoptosis

Oxidative stress and ROS signaling

downin mice11downin reviews3downin human cells2downin cells1+3

20 studies
  1. Nicotinamide mononucleotide decreases oxidative stress and ROS signaling in rats (cyclophosphamide-induced premature ovarian insufficiency).

    “and inhibited granulosa cell apoptosis and oxidative stress in POI rats.”

    Animalscyclophosphamide-induced premature ovarian insufficiency

    Lactate-linked protein change limits death in cultured ovarian cells

    Journal of translational medicine

  2. Nicotinamide mononucleotide decreases oxidative stress and ROS signaling.

    “NMN supplementation enhances mitochondrial function, reduces oxidative stress”

    Reviewovary

    The impact of nicotinamide mononucleotide on ovarian health: A comprehensive literature review of preclinical evidence and therapeutic potential

    Clinical and experimental reproductive medicine

  3. Nicotinamide mononucleotide decreases oxidative stress and ROS signaling in human cells (H2O2-induced and AA-derived hair follicle stem cells).

    “cell apoptosis and oxidative stress were repressed”

    CellsH2O2-induced and AA-derived hair follicle stem cells2 mM

    NMN alleviates oxidative stress damage in alopecia areata by activating SIRT7 and promoting glutamine metabolism

    Biochimica et biophysica acta. Gene regulatory mechanisms

  4. Nicotinamide mononucleotide decreases oxidative stress and ROS signaling in alcohol-fed mice.

    “attenuates hepatic lipid deposition, dysregulated lipid metabolism genes, oxidative stress, and inflammation in ALD mice”

    Animalsin alcohol-fed miceliver

    Hepatic Hamp restoration contributes to nicotinamide mononucleotide (NMN)-alleviated hepatic steatosis in chronic alcohol-fed mice

    Communications biology

  5. Nicotinamide mononucleotide decreases oxidative stress and ROS signaling in D-galactose-induced aging model.

    “NMN alleviates age-related cognitive decline in mice by reducing oxidative stress”

    Animalsin D-galactose-induced aging modelsix weeks

    Targeting the Gut-Brain Axis: Protective Effects of NMN in Alleviating D-Galactose-Induced Cognitive Deficits

    Metabolites

  6. Nicotinamide mononucleotide decreases oxidative stress and ROS signaling in aged mice.

    “reduced oocyte oxidative stress (ROS) and apoptosis”

    Animalsin aged miceoocyte500 mg/kg/day10 daysfemales

    NMN Can Restore Ovarian Reserve in Aged Mice by Upregulating NAD⁺/SIRT1/PGC-1α Signaling Pathway and TOMM20 Expression, and Improve in Vitro Development of Aging Oocytes

    Reproductive sciences (Thousand Oaks, Calif.)

  7. Nicotinamide mononucleotide decreases oxidative stress and ROS signaling in mice (APP/PS1 transgenic Alzheimer's disease model).

    “NMN supplementation also enhanced ATP production, mitochondrial function, and synaptic density in the hippocampus while reducing oxidative stress and Aβ accumulation in the brain.”

    AnimalsAPP/PS1 transgenic Alzheimer's disease modelbrain

    Nicotinamide mononucleotide supplementation modulates gut microbiota and metabolites to mitigate Alzheimer's disease pathology in APP/PS1 mice

    Journal of Alzheimer's disease : JAD

  8. Nicotinamide mononucleotide decreases oxidative stress and ROS signaling in ferric ammonium citrate-overloaded BV-2 cells.

    “down-regulate iron contents and the expression of ferritin and inhibit oxidative stress in iron-overloaded BV-2 microglia cells”

    Cellsin ferric ammonium citrate-overloaded BV-2 cells

    Nicotinamide Mononucleotide Reduces Iron in BV-2 Cell by Up-Regulating Ferroportin 1 via Inhibiting the IL-6/STAT3/Hepcidin Pathway

    Rejuvenation research

  9. Nicotinamide mononucleotide decreases oxidative stress and ROS signaling (animal models).

    “Across animal models, NMN supplementation has been shown to improve mitochondrial regulation, reduce oxidative stress”

    Reviewanimal modelsoocyte

    NMN supplementation as a strategy to improve oocyte quality: a systematic review and transcriptomic analysis

    Journal of assisted reproduction and genetics

  10. Nicotinamide mononucleotide decreases oxidative stress and ROS signaling in mice (chronic and binge ethanol feeding).

    “NMN significantly counteracted the ethanol-induced elevation in liver MDA levels and restored the diminished glutathione (GSH) and superoxide dismutase (SOD) activity levels caused by ethanol exposure.”

    Animalschronic and binge ethanol feedinglivern = 10

    β-Nicotinamide mononucleotide alleviates Alcohol-Induced liver injury in a mouse model through activation of NAD⁺/SIRT1 signaling pathways

    Hereditas

All 20

More on Oxidative stress and ROS signaling

Cellular senescence

downin mice8downin human cells6downin mouse cells4downin cells1

19 studies
  1. Nicotinamide mononucleotide inhibits cellular senescence in human cells.

    “application of the NAD+ precursor β-nicotinamide mononucleotide (NMN) could inhibit the senescence of choroid plexus epithelial cells (CPECs)”

    Cellschoroid plexus epithelial cell

    Reduced cerebrospinal fluid NAD+ is associated with idiopathic normal pressure hydrocephalus and senescence-related alterations

    Frontiers in aging

  2. Nicotinamide mononucleotide decreases cellular senescence in human cells (CGAS-STING1-driven senescence).

    “Consequently, NMN mitigates CGAS-STING1-driven senescence.”

    CellsCGAS-STING1-driven senescencemuscle cell

    NMN/NAD⁺ enhances SIRT2-modulated microtubule dynamics to improve mitochondrial and mitophagy functions in senescent cells

    Autophagy

  3. Nicotinamide mononucleotide decreases cellular senescence in human cells (H2O2-induced oxidative stress in ARPE-19 cells).

    “both free NMN and NMN-GNPs significantly attenuated H2O2-induced apoptosis and cellular senescence in ARPE-19 cells”

    CellsH2O2-induced oxidative stress in ARPE-19 cellsfreeretinal pigment epithelium

    Enhancing retinal cells anti-attenuation under oxidative stress by NMN-loaded gelatin nanoparticles via efficiently intracellular delivery

    International journal of biological macromolecules

  4. Nicotinamide mononucleotide decreases cellular senescence in mice.

    “NMN treatment can improve cellular autophagy, decrease the senescence marker Bcl2, and reduce fibrosis in the heart.”

    Animalsheart

    Administration of Nicotinamide Mononucleotide Mitigates the HIV Nef-Induced Metabolic and Pathological Changes in the Heart

    Cells

  5. Nicotinamide mononucleotide decreases cellular senescence in mice (high-fat diet-fed aging mice) (P < 0.01 for P21 and β-gal; P < 0.05 for SASP markers).

    “decreased the expression concentrations of senescence-associated secretory phenotype markers (Serpine1, MMP3, CXCL-1, CXCL-10, and P16; P < 0.05), senescence markers (P21 and β-galactosidase (β-gal); P < 0.01)”

    Animalshigh-fat diet-fed aging miceheart400 mg/kg in drinking water7 momales

    Nicotinamide Mononucleotide Improves High-Fat Diet-Induced Myocardial Damage of Aging Mice through the Sirt3/PINK1/Parkin Signaling Pathway

    The Journal of nutrition

  6. Nicotinamide mononucleotide decreases cellular senescence in mouse cells (uranium-induced senescence).

    “Administration of nicotinamide mononucleotide (NMN) as NAD+ precursor partially rescued uranium induced senescence in BMSCs”

    Cellsuranium-induced senescence

    Uranium exposure induces osteopenia via mitochondrial dysfunction-driven senescence in bone marrow mesenchymal stem cells

    Journal of hazardous materials

  7. Nicotinamide mononucleotide decreases cellular senescence in human cells (IS-induced in hASMCs).

    “nicotinamide mononucleotide, NMN) or reduced ER stress (via tauroursodeoxycholic acid, TUDCA) attenuated IS-induced ISR activation, osteogenic transdifferentiation, and senescence in hASMCs.”

    CellsIS-induced in hASMCsaortic smooth muscle cell

    Indoxyl Sulfate Drives Vascular Calcification by the mTORC1-ER Stress- Integrated Stress Response Axis

    Research SquarePreprint

  8. Nicotinamide mononucleotide prevents cellular senescence in human cells (pretreatment against platelet-induced senescence in end-stage renal disease).

    “pretreatment with Nicotinamide Mononucleotide is capable of preventing platelet-induced CD8 + T cell senescence in ESRD patients.”

    Cellspretreatment against platelet-induced senescence in end-stage renal diseaseCD8+ T cell

    Platelet-derived microparticles induce CD8+ T cell senescence in end-stage renal disease via the transfer of microRNA-550a-5p

    Research SquarePreprint

  9. Nicotinamide mononucleotide decreases cellular senescence in glycerol model of heme protein-mediated AKI, compared with vehicle.

    “mitigated the severity of the senescence phenotype, as assessed by multiple markers”

    Animalsin glycerol model of heme protein-mediated AKI, compared with vehiclekidneyday 1 after HP-AKI induction

    NAD + -Boosting Ameliorates Heme Protein-Mediated Acute Kidney Injury

    Kidney360

  10. Nicotinamide mononucleotide decreases cellular senescence in cells (NAD+ precursor supplementation).

    “the CD38 inhibitor 78c and the NAD+ precursor β-nicotinamide mononucleotide (NMN), both of which effectively reduced senescence markers”

    CellsNAD+ precursor supplementationtype II alveolar epithelial cells

    Histone H4 Lysine 12 Lactylation Promotes the Senescence of Alveolar Epithelial Type II Cells in Chronic Obstructive Pulmonary Disease by Modulating the CD38-NAD⁺ Signaling Pathway

    Aging and disease

All 19

More on Cellular senescence

Inflammation

downin mice13downin cells1downin human cells1no changein humans1+1

17 studies
  1. Nicotinamide mononucleotide showed no clear effect on inflammation in humans.

    “However, the changes from baseline in hsCRP, IL‐6, and TNF‐alpha levels did not differ between the MIB‐626 and placebo groups.”

    Human trial14 consecutive daysn = 42

    Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial

    FASEB bioAdvances

  2. Nicotinamide mononucleotide decreases inflammation in mice (acute kidney injury).

    “NMN-PEG was found to augment peroxisomal function in PTCs via ACAA1, leading to increased β-oxidation of LCFAs and VLCFAs to mitigate ferroptosis and inflammation.”

    Animalsacute kidney injuryPEGylatedproximal tubule cell

    Modified compound reduced acute kidney injury in mice

    International journal of biological sciences

  3. Nicotinamide mononucleotide increases inflammation in mice.

    “In males, but not females, NMN increased physical activity and boosted metabolic health, whilst also upregulating inflammatory pathways”

    Animalslong-termmales

    Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner

    Research SquarePreprint

  4. Nicotinamide mononucleotide decreases inflammation in cells (LPS challenge).

    “by concurrently suppressing cGAS-STING-mediated inflammation”

    CellsLPS challenge

    NMN mitigates LPS-induced liver injury by inhibiting ferroptosis via suppression of the cGAS-STING-ACSL4 axis

    Pharmacological research

  5. Nicotinamide mononucleotide decreases inflammation in mice (chronic low-dose doxorubicin exposure).

    “Resveratrol and NMN preserve mitochondrial integrity and suppress inflammatory responses in renal tubules.”

    Animalschronic low-dose doxorubicin exposurerenal tubule

    Activation of the NAD⁺–Sirtuin Axis Protects Against Chronic Doxorubicin-Induced Subclinical Renal Tubular Injury Through Restoration of Mitochondrial Homeostasis and Suppression of Inflammation

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

  6. Nicotinamide mononucleotide inhibits inflammation in human cells (TNF-α-induced inflammatory model).

    “Multi-laboratory verification using the novel cosmetic ingredient β-nicotinamide mononucleotide (NMN) confirmed both the anti-inflammatory activity of NMN and the high reproducibility of the assay.”

    CellsTNF-α-induced inflammatory model

    Enhanced Sensitivity and Human Relevance: a TNF-α-Induced HaCaT Keratinocyte Model for Screening Anti-Inflammatory Cosmetic Materials

    Journal of applied toxicology : JAT

  7. Nicotinamide mononucleotide decreases inflammation in mice (arsenic-exposed offspring).

    “NMN supplementation markedly alleviated these inflammatory and neuroimmune disturbances.”

    Animalsarsenic-exposed offspring500 mg/L

    Nicotinamide mononucleotide rescues perinatal arsenic-induced autism-like behaviours via modulation of NAD+ metabolism in mice

    Ecotoxicology and environmental safety

  8. Nicotinamide mononucleotide decreases inflammation in mice (chronic and binge ethanol feeding).

    “It also reduced the release of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, which were triggered by ethanol exposure”

    Animalschronic and binge ethanol feedingn = 10

    β-Nicotinamide mononucleotide alleviates Alcohol-Induced liver injury in a mouse model through activation of NAD⁺/SIRT1 signaling pathways

    Hereditas

  9. Nicotinamide mononucleotide decreases inflammation in mice (combined with antibiotic therapy).

    “The treatment regimen of NMN combined with antibiotics effectively reduced the levels of inflammatory factors in the liver”

    Animalscombined with antibiotic therapyliver

    β-Nicotinamide mononucleotide protects against hypervirulent Klebsiella pneumoniae bloodstream infection and liver injury

    mSphere

  10. Nicotinamide mononucleotide decreases inflammation in mice.

    “NMN exhibited the potential to reduce inflammatory responses, lower serum lipid levels”

    Animals

    Nicotinamide mononucleotide ameliorates hypertriglyceridemia pancreatitis via NAD⁺/SIRT1-mediated TXNIP suppression and NOTCH pathway for accelerated repair-associated processes

    International immunopharmacology

All 17

More on Inflammation

Reactive oxygen species

downin mouse cells5downin mice4downin human cells2downin cells1+3

15 studies
  1. Nicotinamide mononucleotide decreases reactive oxygen species in mouse cells (oxygen-glucose deprivation/reoxygenation).

    “OGD/R exposure induced severe mitochondrial structural damage, intracellular depletion of NAD+ and ATP, and excessive reactive oxygen species (ROS) generation; these pathological phenotypes were partially attenuated by NMN supplementation.”

    Cellsoxygen-glucose deprivation/reoxygenationprimary microglia

    Nicotinamide Mononucleotide Is Associated with Attenuation of OGD/R-Induced Pro-Inflammatory Programs in Microglia: Transcriptomic Evidence Converging on the NLRP3 Inflammasome and Lipid-Droplet-Related Molecular Signatures

    Biomedicines

  2. Nicotinamide mononucleotide decreases reactive oxygen species in mouse cells (D-galactose-aged C2C12 cells).

    “NMN significantly decreased reactive oxygen species (ROS) levels in both aged C2C12 myoblasts and myotubes.”

    CellsD-galactose-aged C2C12 cells

    β-Nicotinamide Mononucleotide Inhibits Cellular Senescence in Mouse C2C12 Skeletal Muscle Cells

    Journal of aging research

  3. Nicotinamide mononucleotide decreases reactive oxygen species in mouse cells (intact cumulus–oocyte complexes).

    “nicotinamide mononucleotide (NMN) increased glutathione, reduced ROS and improved mitochondrial membrane potential in oocytes from aged mice”

    Cellsintact cumulus–oocyte complexesoocytefemales

    Aging is linked to weaker metabolic support for mouse eggs

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

  4. Nicotinamide mononucleotide decreases reactive oxygen species in cells (high glucose/high fat-induced injury).

    “In vitro, NMN enhanced cell viability, suppressed apoptosis and total ROS”

    Cellshigh glucose/high fat-induced injury100 μM

    Nicotinamide mononucleotide ameliorates high glucose/high fat-induced cardiomyocyte metabolic dysfunction through SIRT1-mediated CPT1A stabilization

    Molecular biology reports

  5. Nicotinamide mononucleotide decreases reactive oxygen species in human cells (reversal of PS-NPs-induced increase in vitro).

    “all of which were effectively reversed by NMN via the restoration of cellular antioxidant capacity”

    Cellsreversal of PS-NPs-induced increase in vitrosperm

    The presence of microplastics in human semen and the protective role of nicotinamide mononucleotide against polystyrene nanoplastics-induced reproductive and early embryonic toxicity

    Journal of hazardous materials

  6. Nicotinamide mononucleotide decreases reactive oxygen species in dog cells (compared with Ctrl group).

    “decreased the activities of ROS and MDA”

    Cellscompared with Ctrl group

    Nicotinamide Mononucleotide Modulates Endothelin-1 via NR4A1 and Histone Modifications in Canine Intestinal Epithelial Cells

    Animals : an open access journal from MDPI

  7. Nicotinamide mononucleotide decreases reactive oxygen species in oocytes after prolonged maturation.

    “Notably, supplementation with 100 μM NMN reversed these negative effects, significantly increasing the total number of blastocyst cells, reducing ROS levels”

    Cellsin oocytes after prolonged maturation100 μM

    Nicotinamide mononucleotide supplement combined with prolonging maturation time improves the quality of oocytes cultured in vitro

    Animal reproduction science

  8. Nicotinamide mononucleotide decreases reactive oxygen species in mice during cyclophosphamide treatment.

    “reduced reactive oxygen species (ROS) levels, alleviated DNA damage, and reduced apoptosis”

    Animalsduring cyclophosphamide treatmentovary14 daysfemales

    Nicotinamide mononucleotide protects ovarian function and oocyte developmental competence during chemotherapy

    Journal of ovarian research

  9. Nicotinamide mononucleotide decreases reactive oxygen species in mice (chemotherapy-induced premature ovarian insufficiency model) (P=.039).

    “In the premature ovarian insufficiency model, reduced reactive oxygen species abundance (P=.039)”

    Animalschemotherapy-induced premature ovarian insufficiency modeloocytes2 g/L in drinking water4 weeksfemales

    Nicotinamide mononucleotide supplementation improves oocyte developmental competence in different ovarian damage conditions

    American journal of obstetrics and gynecology

  10. Nicotinamide mononucleotide decreases reactive oxygen species in mouse cells (LPS-treated granulosa cells).

    “NMN supplementation significantly reduced reactive oxygen species ROS”

    CellsLPS-treated granulosa cellsgranulosa cell

    Nicotinamide Mononucleotide Restores NAD⁺ Levels to Alleviate LPS-Induced Inflammation via the TLR4/NF-κB/MAPK Signaling Pathway in Mice Granulosa Cells

    Antioxidants (Basel, Switzerland)

All 15

More on Reactive oxygen species

SIRT1

upin mice8upin cells1upin reviews1

10 studies
  1. Nicotinamide mononucleotide increases SIRT1 in mice (cisplatin-induced acute kidney injury).

    “NMN elevated kidney NAD+ levels and enhanced SIRT1 expression.”

    Animalscisplatin-induced acute kidney injurykidneymales

    NMN protects cisplatin-associated AKI via NAD⁺/SIRT1 pathway

    Frontiers in immunology

  2. Nicotinamide mononucleotide increases SIRT1 (100-fold SIRT1 increase).

    “NMN supplementation (100-fold SIRT1 increase)”

    Review

    Six Roads to One Target: SIRT1-PGC-1α Convergence Therapy for Long COVID

    Zenodo (CERN European Organization for Nuclear Research)Preprint

  3. Nicotinamide mononucleotide activates SIRT1 in mice (chronic and binge ethanol feeding).

    “NMN activated the NAD+/ SIRT1 signaling pathway, leading to the upregulation of all target genes.”

    Animalschronic and binge ethanol feedingn = 10

    β-Nicotinamide mononucleotide alleviates Alcohol-Induced liver injury in a mouse model through activation of NAD⁺/SIRT1 signaling pathways

    Hereditas

  4. Nicotinamide mononucleotide increases SIRT1 in SIRT3 knockout mice.

    “stimulated the expression of SIRT1 protein”

    Animalsin SIRT3 knockout mice14 days

    NMN improves cardiac function in SIRT3 knockout mice via the SIRT1/PGC-1α pathway

    Scientific reports

  5. Nicotinamide mononucleotide increases SIRT1 in PCOS oocytes.

    “NMN supplementation upregulates SIRT1 expression”

    Animalsin PCOS oocytesoocytefemales

    Reverse Effects of Nicotinamide Mononucleotide Supplementation on Declining Quality of Oocytes With Polycystic Ovary Syndrome

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

  6. Nicotinamide mononucleotide activates SIRT1 in cells (UVB-induced damage).

    “In conclusion, NMN activated SIRT1, inhibiting mitochondrial dysfunction, oxidative stress, and senescence in LEC, delaying lens opacity.”

    CellsUVB-induced damagelens epithelial cells

    SIRT1 Prevents Lens Epithelial Cell Senescence During Age-Related Cataract via Regulating p66Shc

    Aging cell

  7. Nicotinamide mononucleotide increases SIRT1 in ageing mice.

    “NMN increased the expression of the proteins SIRT1, NMNAT2, and NMNAT3 and decreased the expression of the protein P53.”

    Animalsin ageing micelong-term

    β-Nicotinamide mononucleotide supplementation prolongs the lifespan of prematurely aged mice and protects colon function in ageing mice

    Food & function

  8. Nicotinamide mononucleotide increases SIRT1 in mice (imiquimod-treated mice).

    “NMN treatment reversed the SIRT1 decline in the mouse model.”

    Animalsimiquimod-treated mice

    The Role of Nicotinamide Mononucleotide Supplementation in Psoriasis Treatment

    Antioxidants (Basel, Switzerland)

  9. Nicotinamide mononucleotide increases SIRT1 in mice (LPS-induced sepsis).

    “upregulated the expression of SIRT1”

    AnimalsLPS-induced sepsislung500 mg/kg12 hn = 8

    Nicotinamide mononucleotide alleviates endotoxin-induced acute lung injury by modulating macrophage polarization via the SIRT1/NF-κB pathway

    Pharmaceutical biology

  10. Nicotinamide mononucleotide increases SIRT1 in mice (100 mg/kg/d dose; JAK1, STAT3, YAP1, GHR and IGF-1 expression also increased).

    “the expression of SIRT1, JAK1, STAT3, YAP1, GHR and IGF-1 was increased”

    Animals100 mg/kg/d dose; JAK1, STAT3, YAP1, GHR and IGF-1 expression also increasedliver100 mg/kg/d21 days

    NMN supplementation promotes liver growth-The result of the regulated transcription and metabolism

    Research SquarePreprint

More on SIRT1

Ferroptosis

downin cells2downin mice2downin human cells1downin mouse cells1+1

7 studies
  1. Nicotinamide mononucleotide decreases ferroptosis in mice (acute kidney injury).

    “NMN-PEG was found to augment peroxisomal function in PTCs via ACAA1, leading to increased β-oxidation of LCFAs and VLCFAs to mitigate ferroptosis and inflammation.”

    Animalsacute kidney injuryPEGylatedproximal tubule cell

    Modified compound reduced acute kidney injury in mice

    International journal of biological sciences

  2. Nicotinamide mononucleotide decreases ferroptosis in cells (LPS challenge).

    “NMN effectively reverses these pathological changes”

    CellsLPS challenge

    NMN mitigates LPS-induced liver injury by inhibiting ferroptosis via suppression of the cGAS-STING-ACSL4 axis

    Pharmacological research

  3. Nicotinamide mononucleotide decreases ferroptosis in cells (high-altitude hypoxia-induced microglial ferroptosis).

    “exogenous addition of NMN ameliorates ferroptosis”

    Cellshigh-altitude hypoxia-induced microglial ferroptosismicroglia

    NMN mitigates high-altitude hypoxia-induced cognitive impairment by inhibiting microglial ferroptosis

    Biochemical and biophysical research communications

  4. Nicotinamide mononucleotide inhibits ferroptosis in aluminum oxide nanoparticle-exposed mice.

    “NMN protects against cognitive impairment and neuronal injury, at least in part, by suppressing ferroptosis-related processes.”

    Animalsin aluminum oxide nanoparticle-exposed mice

    Nicotinamide Mononucleotide Ameliorates Nano-Aluminum Oxide-Induced Cognitive Impairment and Ferroptosis via the GSH/GPX4 Axis

    Small (Weinheim an der Bergstrasse, Germany)

  5. Nicotinamide mononucleotide inhibits ferroptosis in human cells (H2O2-induced cell death).

    “NMN could effectively inhibit the apoptosis and ferroptosis pathways, thus protected cells from H2O2-induced cell death”

    CellsH2O2-induced cell deathA549 cells

    Protective effects of nicotinamide mononucleotide on DNA damage and cell death in A549 cells and aging in C. elegans caused by hydrogen peroxide

    Mutation research. Genetic toxicology and environmental mutagenesis

  6. Nicotinamide mononucleotide inhibits ferroptosis in hyperoxia-aggravated septic lung injury.

    “Similarly, NMN inhibited ferroptosis in hyperoxia-aggravated septic lung injury.”

    Animalsin hyperoxia-aggravated septic lung injurylung

    Nicotinamide mononucleotide mitigates hyperoxia-aggravated septic lung injury via the GPx4-mediated anti-ferroptosis signaling pathway in alveolar epithelial cells

    Free radical biology & medicine

  7. Nicotinamide mononucleotide decreases ferroptosis in mouse cells (LPS-induced ferroptosis in microglia).

    “NMN effectively rescued LPS-induced ferroptosis and improved cell viability in microglia”

    CellsLPS-induced ferroptosis in microgliamicroglia

    Nicotinamide mononucleotide mitigates neuroinflammation by enhancing GPX4-mediated ferroptosis defense in microglia

    Brain research

More on Ferroptosis

Mitochondrial function

upin mice4upin human cells2upin rats1

7 studies
  1. Nicotinamide mononucleotide improves mitochondrial function in mice (renal ischemia-reperfusion injury model).

    “restoring mitochondrial function and ameliorating renal damage in AKI mice”

    Animalsrenal ischemia-reperfusion injury modelloaded in NKN-LNPkidney

    Neutrophil-Driven Cascade-Targeted Nanocarriers Restore Mitochondrial Homeostasis to Ameliorate Renal Ischemia-Reperfusion Injury

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

  2. Nicotinamide mononucleotide improves mitochondrial function in mice (APP/PS1 transgenic Alzheimer's disease model).

    “NMN supplementation also enhanced ATP production, mitochondrial function, and synaptic density in the hippocampus”

    AnimalsAPP/PS1 transgenic Alzheimer's disease modelhippocampus

    Nicotinamide mononucleotide supplementation modulates gut microbiota and metabolites to mitigate Alzheimer's disease pathology in APP/PS1 mice

    Journal of Alzheimer's disease : JAD

  3. Nicotinamide mononucleotide improves mitochondrial function in long-photoperiod-exposed rats.

    “Treatment with the NAD+ metabolic precursor nicotinamide mononucleotide could ameliorate mitochondria function”

    Animalsin long-photoperiod-exposed rats

    Circadian rhythm disruption impairs ovarian follicular development via NAD⁺ metabolic reprogramming

    EBioMedicine

  4. Nicotinamide mononucleotide increases mitochondrial function in human cells under oxidative stress or photo-aging models.

    “enhanced mitochondrial function”

    Cellsunder oxidative stress or photo-aging modelsskin fibroblasts

    Distinctive Gene Expression Profiles and Biological Responses of Skin Fibroblasts to Nicotinamide Mononucleotide: Implications for Longevity Effects on Skin

    Biomedicines

  5. Nicotinamide mononucleotide improves mitochondrial function in human cells (patient-derived HGPS cells).

    “NMN supplementation enhanced NAD+ biosynthesis, restored mitochondrial function, reduced DNA damage, and mitigated oxidative stress.”

    Cellspatient-derived HGPS cellsinduced pluripotent stem cell-derived mesenchymal stem cells

    Nicotinamide Mononucleotide Alleviates Aging Defects in Hutchinson-Gilford Progeria Syndrome

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

  6. Nicotinamide mononucleotide improves mitochondrial function in PCOS oocytes.

    “NMN helps reverse the decline in PCOS oocyte quality by mitigating oxidative stress, improving mitochondrial function, and preserving spindle morphology”

    Animalsin PCOS oocytesoocytefemales

    Reverse Effects of Nicotinamide Mononucleotide Supplementation on Declining Quality of Oocytes With Polycystic Ovary Syndrome

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

  7. Nicotinamide mononucleotide improves mitochondrial function in oocytes from streptozotocin-induced diabetic mice.

    “improving the mitochondrial function, reducing ROS level, suppressing DNA damage”

    Animalsin oocytes from streptozotocin-induced diabetic mice

    Nicotinamide Mononucleotide improves oocyte maturation of mice with type 1 diabetes

    Nutrition & diabetes

Insulin resistance

downin rats2downin animals1downin humans1downin mice1

5 studies
  1. Nicotinamide mononucleotide decreases insulin resistance in rats (letrozole- and high-fat diet-induced PCOS).

    “NMN supplementation significantly reversed insulin resistance, hyperandrogenism, estrous cycle disorder, and polycystic ovarian morphology in PCOS rats”

    Animalsletrozole- and high-fat diet-induced PCOS500 mg/kg/d30 days

    Nicotinamide mononucleotide supplementation improves polycystic ovary syndrome by activating silent regulatory protein 2 mediated lactate dehydrogenase A lysine 119 deacetylation to enhance glycolytic activity

    International journal of biological macromolecules

  2. Nicotinamide mononucleotide decreases insulin resistance in rats (letrozole and high-fat diet-induced PCOS model).

    “NMN inhibits endometrial cell apoptosis, improves endometrial decidualization transition, reduces IR”

    Animalsletrozole and high-fat diet-induced PCOS modeluterusfemales

    Nicotinamide Mononucleotide Improves Endometrial Homeostasis in a Rat Model of Polycystic Ovary Syndrome by Decreasing Insulin Resistance and Regulating the Glylytic Pathway

    Molecular nutrition & food research

  3. Nicotinamide mononucleotide decreases insulin resistance in humans (small-dose subgroup).

    “administering a small dose of NMN exerted the most prominent impact on Homeostasis Model Assessment-Insulin Resistance (HOMA-IR).”

    Reviewsmall-dose subgroupsmall dose

    Effects of Nicotinamide Mononucleotide Supplementation on Muscle and Liver Functions Among the Middle-aged and Elderly: A Systematic Review and Meta-analysis of Randomized Controlled Trials

    Current pharmaceutical biotechnology

  4. Nicotinamide mononucleotide decreases insulin resistance in chronic high-fat diet-fed mice.

    “NMN improved liver steatosis and insulin resistance in chronic high-fat diet (HFD) mice.”

    Animalsin chronic high-fat diet-fed miceliver

    Alleviation of hepatic insulin resistance and steatosis with NMN via improving endoplasmic reticulum-Mitochondria miscommunication in the liver of HFD mice

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

  5. Nicotinamide mononucleotide prevents insulin resistance during high-fat diet-induced lipid overload.

    “prevented CD36-mediated lipid accumulation, CD36-TLR4 interaction toward inflammation, fibrosis, cardiac dysfunction, and whole-body insulin resistance”

    Animalsduring high-fat diet-induced lipid overload

    Glycolysis-Mediated Activation of v-ATPase by Nicotinamide Mononucleotide Ameliorates Lipid-Induced Cardiomyopathy by Repressing the CD36-TLR4 Axis

    Circulation research

More on Insulin resistance

Acute kidney injury

downin mice2no changein humans1

3 studies
  1. Nicotinamide mononucleotide showed no clear effect on acute kidney injury in humans.

    “The changes in serum creatinine levels from baseline over the 14‐day intervention period did not differ significantly between groups.”

    Human trial14 consecutive daysn = 42

    Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial

    FASEB bioAdvances

  2. Nicotinamide mononucleotide decreases acute kidney injury in mice (acute kidney injury).

    “PEGylation increased the preferential uptake of NMN in mice renal cortex, enhancing its alleviating effect on AKI.”

    Animalsacute kidney injuryPEGylatedkidney

    Modified compound reduced acute kidney injury in mice

    International journal of biological sciences

  3. Nicotinamide mononucleotide protects against acute kidney injury in Kynu-/- mice.

    “Supplementation with nicotinamide mononucleotide, an NAD + precursor, significantly alleviated AKI in Kynu-/- mice.”

    Animalsin Kynu-/- micekidneyfemales

    Sex Dimorphism of NAD +De Novo Biosynthesis Mediates Sex-Biased Susceptibility to Ischemia-Reperfusion-Induced Acute Kidney Injury

    Journal of the American Society of Nephrology : JASN

More on Acute kidney injury

Diastolic blood pressure

downin humans2

2 studies
  1. Nicotinamide mononucleotide decreases diastolic blood pressure in humans (compared with placebo) (WMD -2.15 mmHg).

    “Compared with the placebo, NMN supplementation was associated with a statistically significant but modest reduction in resting DBP (WMD, -2.15 mmHg; 95% CI: -3.68 to -0.61).”

    Human trialcompared with placebo

    Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Nutrients

  2. Nicotinamide mononucleotide decreases diastolic blood pressure in humans (short-term supplementation) (slight decrease).

    “Diastolic blood pressure decreased slightly”

    Reviewshort-term supplementation250-2000 mg/day14 days to 24 weeks

    Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis

    Nutrients

More on Diastolic blood pressure

Adverse events

no changein humans2

2 studies
  1. Nicotinamide mononucleotide showed no clear effect on adverse events in humans (oral administration).

    “Systematic and ophthalmic adverse events were not observed in the NMN group.”

    Human trialoral administration250 mg/day24 weeksmalesn = 7

    Effect of Nicotinamide Mononucleotide on Retinal Thickness of Older Patients With Diabetes Mellitus: A Placebo-Controlled, Double-Blind Study

    Geriatrics & gerontology international

  2. Nicotinamide mononucleotide showed no clear effect on adverse events in humans (short-term supplementation).

    “NMN did not increase overall, serious, withdrawal-related, or system-specific adverse events”

    Reviewshort-term supplementation250-2000 mg/day14 days to 24 weeks

    Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis

    Nutrients

Blood NAD+ concentration

upin humans2

2 studies
  1. Nicotinamide mononucleotide increases blood NAD+ concentration in humans (hospitalized patients with COVID-19 and AKI) (16.0 ± 6.9 μg/mL at baseline to 42.6 ± 25.6 μg/mL at day 14).

    “MIB-626 treatment significantly but gradually raised blood NAD+ levels to a peak between 5 to 14 days”

    Human trialhospitalized patients with COVID-19 and AKIMIB-626 tablets1.0 g twice daily14 days

    Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial

    FASEB bioAdvances

  2. Nicotinamide mononucleotide increases blood NAD+ concentration in humans.

    “Random-effects meta-analyses found an overall significant effect of NMN supplementation in elevating blood NAD levels.”

    Review

    Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials

    Critical reviews in food science and nutrition

More on Blood NAD+ concentration

Systolic blood pressure

downin humans1no changein humans1

1 study
  1. Nicotinamide mononucleotide decreases systolic blood pressure in humans (subgroup analysis of adults aged 60 years and older) (WMD -3.94 mmHg).

    “NMN supplementation resulted in a significant reduction in SBP specifically among participants aged 60 years and older (WMD: -3.94 mmHg; 95% CI: -7.06 to -0.82).”

    Human trialsubgroup analysis of adults aged 60 years and older

    Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Nutrients

  2. Nicotinamide mononucleotide showed no clear effect on systolic blood pressure in humans (all adults in pooled analysis).

    “In contrast, the reduction in resting SBP was not statistically significant.”

    Human trialall adults in pooled analysis

    Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Nutrients

More on Systolic blood pressure

All 527

What is nicotinamide mononucleotide linked with?

14

Studies link nicotinamide mononucleotide with 14 measures, among them LPS-altered metabolomic features, lipid-droplet-associated marker transcripts and inflammation.

LPS-altered metabolomic features

mixedin human cells1

1 study
  1. Nicotinamide mononucleotide is associated with LPS-altered metabolomic features in human cells (Pg LPS-stimulated cells) (30 features changed in the opposite direction to LPS-induced changes).

    “Following false discovery rate correction, 30 features altered by LPS showed significant changes in the opposite direction following NMN co-treatment.”

    CellsPg LPS-stimulated cellshuman periodontal ligament cells

    Nicotinamide mononucleotide replenishes intracellular NAD⁺ and is associated with metabolic changes in LPS-stimulated human periodontal ligament cells

    Frontiers in dental medicine

More on LPS-altered metabolomic features

Lipid-droplet-associated marker transcripts

downin mouse cells1

1 study
  1. Nicotinamide mononucleotide is associated with lipid-droplet-associated marker transcripts in mouse cells (oxygen-glucose deprivation/reoxygenation).

    “NMN treatment was associated with reduced transcript levels of Nlrp3, Casp1, Hilpda, and Plin2”

    Cellsoxygen-glucose deprivation/reoxygenationprimary microglia

    Nicotinamide Mononucleotide Is Associated with Attenuation of OGD/R-Induced Pro-Inflammatory Programs in Microglia: Transcriptomic Evidence Converging on the NLRP3 Inflammasome and Lipid-Droplet-Related Molecular Signatures

    Biomedicines

More on Lipid-droplet-associated marker transcripts

Inflammation

downin mouse cells1

1 study
  1. Nicotinamide mononucleotide is associated with inflammation in mouse cells (oxygen-glucose deprivation/reoxygenation).

    “NMN treatment correlates with mitigation of OGD/R-provoked pro-inflammatory remodeling in microglia”

    Cellsoxygen-glucose deprivation/reoxygenationprimary microglia

    Nicotinamide Mononucleotide Is Associated with Attenuation of OGD/R-Induced Pro-Inflammatory Programs in Microglia: Transcriptomic Evidence Converging on the NLRP3 Inflammasome and Lipid-Droplet-Related Molecular Signatures

    Biomedicines

More on Inflammation

Gut microbiota composition

mixedin mice1

1 study
  1. Nicotinamide mononucleotide is associated with gut microbiota composition in mice (intermittent normobaric hypoxia).

    “restored the spleen weight and index, and changed the composition of the gut microbiota.”

    Animalsintermittent normobaric hypoxiagut

    Nicotinamide Mononucleotide Does Not Prevent Cardiac Hypertrophy but Attenuates Cardiac Stress and Remodeling Markers in Mice Exposed to Intermittent Normobaric Hypoxia

    Nutrients

More on Gut microbiota composition

TGF-β-associated transcriptional changes

mixedin mouse cells1

1 study
  1. Nicotinamide mononucleotide is associated with TGF-β-associated transcriptional changes in mouse embryonic fibroblasts.

    “In mouse embryonic fibroblasts, NMN partially restored a subset of TGF-β-associated transcriptional changes”

    Cellsin mouse embryonic fibroblasts

    NAD⁺ metabolism influences TGF-β-associated transcriptional programs and the gut microbiota in murine models of colitis

    Biochemistry and biophysics reports

Mitochondrial DNA copy number

mixedin mice1

1 study
  1. Nicotinamide mononucleotide is associated with mitochondrial DNA copy number in mice (increased in small mitochondria and decreased in large mitochondria).

    “increasing mitochondrial DNA copy number above both young and aged levels in small mitochondria while further reducing it below aged levels in large mitochondria.”

    Animalsincreased in small mitochondria and decreased in large mitochondriacumulus granulosa cell

    Mouse egg cells show age-related changes missed by averages

    Journal of ovarian research

More on Mitochondrial DNA copy number

NAD+ metabolic enzymes

mixedin human cells1

1 study
  1. Nicotinamide mononucleotide is associated with NAD+ metabolic enzymes in human cells.

    “high-dose NMN treatment could alter the level of several key NAD+ metabolic enzymes in human immune cells”

    Cellshigh-dose

    Nicotinamide mononucleotide enhances anti-tumor effect by resetting macrophages toward the inflammatory M1-like phenotype

    Molecular therapy. Oncology

Gut microbial composition

mixedin mice1

1 study
  1. Nicotinamide mononucleotide is associated with gut microbial composition in mice (APP/PS1 transgenic Alzheimer's disease model).

    “NMN administration significantly altered gut microbial composition and fecal metabolite profiles”

    AnimalsAPP/PS1 transgenic Alzheimer's disease modelgut

    Nicotinamide mononucleotide supplementation modulates gut microbiota and metabolites to mitigate Alzheimer's disease pathology in APP/PS1 mice

    Journal of Alzheimer's disease : JAD

More on Gut microbial composition

Microbiome composition

mixedin reviews1

1 study
  1. Nicotinamide mononucleotide is associated with microbiome composition.

    “NMN influencing microbial composition and diversity, while the microbiota modulates NMN metabolism and bioavailability.”

    Review

    Interplay Between Nicotinamide Mononucleotide and Microbiota: A New Avenue in Metabolic Health

    Food Reviews International

More on Microbiome composition

Autophagy

upin mice1

1 study
  1. Nicotinamide mononucleotide is associated with autophagy in mice (tail-suspension (simulated microgravity)).

    “These cardioprotective effects of NAD+ repletion were associated with the reduction of oxidative stress and improvement of autophagic flux.”

    Animalstail-suspension (simulated microgravity)heart100 mg/kg body weight28 days

    Administration of β-Nicotinamide Mononucleotide Attenuates Myocardial Dysfunction in Tail-Suspended Mice

    Journal of cardiovascular pharmacology and therapeutics

More on Autophagy

All 14

Has nicotinamide mononucleotide been tested in people?

8 of 11 about aging

Yes: 33 trials and 16 observational studies in people have been published, and 6 trials are registered.

Latest change Phase 1/2 → Phase 2Oct 19, 2026

Every condition in trials

  • Purpura, Thrombocytopenic, Idiopathic

    Phase 1/2Recruiting1 trial

  • Enhance immune function

    Early phase 1Status unknown1 trial

  • Aging

    No phaseCompleted2 trials

  • Aging

    No phaseRecruiting1 trial

  • Frailty

    No phaseRecruiting1 trial

Who is developing nicotinamide mononucleotide?

1 company: Metro International Biotech.

Companies
  • Metro International BiotechMIB-626Phase 2diabetic kidney disease, Alzheimer's disease

Trial sponsors

Funding

13 grants since 2018

Japan Society for the Promotion of Science¥45MUS Department of Veterans AffairsNational Institute of Dental and Craniofacial Research$466K

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    A preprint reports longer lifespan in female mice; independent labs report reduced oxidative stress but opposing inflammation changes in mice. Human trials report increased blood NAD+; six trials concern aging, and two across all uses ended over a year ago without posted results. The National Natural Science Foundation of China supports 322 findings; company employees coauthor papers, and companies sponsor most trials.

  2. Summary rewritten as its findings changed.

    As it read before

    A preprint reports longer female mouse lifespan with nicotinamide mononucleotide; independent labs report mouse NAD+ increases and opposing inflammation changes, while human trials raise blood NAD+. Six registered trials concern aging; four trials ended over a year ago without posted results or linked papers. Papers name National Natural Science Foundation of China funding and developer ties; companies sponsor six trials.

  3. Summary rewritten as its findings changed.

    As it read before

    A mouse preprint reports longer female lifespan with nicotinamide mononucleotide; independent labs report reduced senescence in human cells and improved human sleep quality. Human trials raise blood NAD+; insulin-resistance results differ. Six trials concern aging; across all uses, four ended over a year ago without posted results or linked papers, and most are sponsored by MetroBiotech, Abinopharm and Shanghai Cell Therapy Group.

  4. Summary rewritten as its findings changed.

    As it read before

    NMN extends lifespan in HGPS-model mice; independent labs reproduce mouse NAD+ increases and oxidative-stress reductions, but inflammation results conflict. Human results here come from one group; two registered trials concern aging, two trials ended over a year ago without posted results, and authors have company affiliations and companies sponsor trials.

  5. Summary rewritten as its findings changed.

    As it read before

    Independent labs reproduce increased SIRT3 in mice; inflammation usually decreases but increases in a male-mouse preprint. Human work comes from one group. Two trials ended over a year ago without posted results or citing papers; Abinopharm and Shanghai Cell Therapy Group sponsor two of five trials, and the National Natural Science Foundation of China supports 10 findings.

Latest

Dec 2025: 7Jan 2026: 13Feb 2026: 25Mar 2026: 23Apr 2026: 15May 2026: 9Jun 2026: 16Jul 2026: 14Aug 2026: 17Sep 2026: 13Oct 2026: 21Nov 2026: 8181 papers in 12 months
Journal of Translational Medicine

Lactate-linked protein change limits death in cultured ovarian cells

A lactate-based protein modification supported transport channels and reduced cell death in experiments with lab-grown granulosa cells, which support developing eggs.A lactate-based protein modification supported transport channels and reduced cell death in experiments with lab-grown granulosa cells, which support developing eggs.

Human cell studyReproductive system
bioRxiv

Cell stress linked to disrupted metabolism in goat egg cells

In goat egg-cell experiments, a supplement restored a metabolic molecule, improved measures of cell function and improved early embryo development.In goat egg-cell experiments, a supplement restored a metabolic molecule, improved measures of cell function and improved early embryo development.

Preprint: animal cell studyInterventions
Journal of Ovarian Research

Mouse egg cells show age-related changes missed by averages

Sorting individual mitochondria in mouse egg cells revealed age-related DNA differences that pooled measurements missed, with supplementation producing different effects…Sorting individual mitochondria in mouse egg cells revealed age-related DNA differences that pooled measurements missed, with supplementation producing different effects across groups.

Animal cell studyInterventions
International Journal of Molecular Sciences

Cream did not protect mouse skin from repeated ultraviolet damage

Female mice given 5% nicotinamide mononucleotide cream after ultraviolet B exposure three times weekly through week 25 showed no protection against skin damage.Female mice given 5% nicotinamide mononucleotide cream after ultraviolet B exposure three times weekly through week 25 showed no protection against skin damage.

Mouse studySkin

See all 826 papers on nicotinamide mononucleotide